Market News & Trends
Enzene launches NeX, a comprehensive suite of solutions to enable cost-efficient, high-yielding local biomanufacturing
Pune, India - Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO™), today announced the launch of NeX, a transformative end-to-end partnership model…
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
CAMBRIDGE, Mass., Obsidian Therapeutics, Inc., a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced the completion…
Tasrif Pharmaceutical Granted Second U.S. Patent for CD155-Targeting Antibody Developed with Abzena’s Humanization & Immunogenicity Platforms
Abzen’s customer Tasrif Pharmaceutical, LLC announced the grant of its second U.S. Patent, expanding its intellectual property targeting the Poliovirus Receptor (CD155/PVR). Together with Tasrif’s…
Abzena’s Customer Promatix Awarded Innovate UK Biomedical Catalyst Grant to Advance Cis-Bispecific ADC
Promatix Biosciences Ltd, an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, announced that it has been awarded a…
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Stevanato Group S.p.A., a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced…
Pace Life Sciences Announces Compliant US FDA Inspection of Operations in Research Triangle Park, NC
RALEIGH, NC Pace® Life Sciences, a U.S.-based, FDA-registered GMP analytical testing laboratory and full-service contract research, development, and manufacturing organization (CDMO), and a Division of Pace®,…
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
CAMBRIDGE, Mass., -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in…
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division
Garching / Munich, Germany and Princeton, New Jersey, - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today introduced Lumara Bio as a…
Nemera and SCHOTT Pharma deliver verified pen injector platform with sterile cartridge system
To support the industry shift from hospital to homecare including a more convenient drug administration for patients, Nemera, a world-leading provider of drug delivery device…
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development
Basel, Switzerland, and London, UK – Lonza, a contract development and manufacturing organization (CDMO), and Engitix, a global leader in ECM-based drug discovery and development,…
Samsung Biologics announces all-cash offer to acquire PolyPeptide
INCHEON, South Korea, -- Samsung Biologics has announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital…
Eli Lilly Makes $2.8 Billion Neuropsychiatry Acquisition
Another major move from Lilly - this time putting real capital behind psychedelics as a legitimate mental health treatment class. Why this matters: Treatment-resistant depression…
CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development
MONTREAL, CANADA, – CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced the launch of its Global Digital Pathology and AI Consortium,…
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Paris, The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with…
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
DURHAM, NC, Atsena Therapeutics, a clinical-stage gene therapy company focused on reversing and preventing blindness from inherited retinal diseases, today announced the selection of a…
Gattefossé accelerates production ramp-up at its Lufkin facility with eight validated ingredients
Gattefossé, a leading provider of specialty ingredients and formulation solutions for the pharmaceutical and personal care industries, announces the successful validation of eight strategic ingredients…
Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus (ocrelizumab) for Multiple Sclerosis
TEL AVIV, ISRAEL, and Zug, Switzerland - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd and Polpharma Biologics International AG today announced…
Evonik invests US$100 million to upgrade its U.S. drug substance contract manufacturing site
Essen, Germany. Evonik is making a significant investment to strengthen manufacturing capabilities at its Lafayette (Tippecanoe), Indiana facility. Over the next five years, the company…
Fonseca Biosciences Launches XTORO (finafloxacin otic suspension) 0.3% for Acute Otitis Externa
LONG BEACH TOWNSHIP, N.J. — Fonseca Biosciences, a specialty pharmaceutical company commercializing clinically differentiated pharmaceutical products, today announced the launch of XTORO (finafloxacin otic suspension),…
FUJIFILM Biotechnologies Selected in FDA PreCheck Pilot Program to Advance U.S. Drug Manufacturing
HOLLY SPRINGS, NC, FUJIFILM Biotechnologies (Fujifilm), a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced that its commercial-scale…
